Alliance Reports Positive Results in Chronic Pain Relief from the Leading-Edge Proprietary CBD DANA Hemp Strain
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2018) - Alliance Growers Corp. (CSE: ACG) (FSE: 1LA) (WKN: A2DFYX) (OTC: ALGWF) ("Alliance Growers" or the "Company") is pleased to report that recent informal trials whereby patients were treated with the "CBD DANA" strain, show extremely promising results in helping provide effective relief for individuals stricken with chronic pain.
Alliance Growers, via its strategic partnership with Pharmagreen Biotech Inc. (formerly known as WFS Pharmagreen Inc.), has secured access to a proprietary CBD strain named "CBD DANA,". The unique strain has been tested for a content of at least 12% CBD and less than 0.3% THC. This CBD yield is substantially greater than traditional hemp strains which typically have at most a 1% content of CBD. The lower THC content allows the strain to be classified as "industrial hemp" which makes it ideal for cultivation with less restrictive regulation.
The female plantlets produced in the Tissue Culture Lab at the Cannabis Biotech Complex will be available for our own commercial hemp operations and for hemp farmers on a global scale. Providing all female, fully rooted tissue-cultured plantlets of the strain will provide a significant yield in CBD production for hemp farmers.
The informal tests that are currently ongoing are unique in that the raw flower material is grinded down and not extracted. Therefore, the 'whole plant' benefits are realized and provides the healing 'entourage effect' with great success. The informal tests are conducted with individuals possessing a prescription from their attending physician and have a license to possess from Health Canada.
Alliance Growers is also pleased to report that Cannabis Compliance Inc., the ACMPR consultants to Pharmagreen Biotech Inc., have submitted two licensing applications to Health Canada. One is for an ACMPR license — to grow and sell tissue cultured plantlets, and the second is for a Dealer License — to extract, formulate, package and sell cannabis derivatives.
Additionally, the Company reports that the Engineering plans for the Cannabis Biotech Complex are developing and moving forward as planned.
Commenting on the successful trials and the progress at the Cannabis Biotech Complex, Dennis Petke, Alliance Growers President and CEO stated, "The products produced from the CBD Dana strain and from Cannabis CBD oil will give Alliance Growers and its group of companies a significant advantage in cost and margin compared to competitors. Spyder Vapes Inc., an established, upscale, 'high-end stores without high-end prices' retail chain will provide the perfect distribution channel for these highly effective Pharmagreen and Alliance Growers branded products. We are thrilled to be executing on our strategy to take Alliance Growers to where the market is going, not where it is today."
About Alliance Growers Corp.
Alliance Growers is a diversified cannabis company driven by the Company's 'Four Pillars' Organization Plan — Cannabis Biotech Complex, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Technology.
Alliance Growers is working with Pharmagreen Biotech Inc. advancing a new business partnership, to jointly develop and operate a 58,000-square foot facility, to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Biotech Complex will grow Cannabis plantlets using proprietary tissue culture propagation, specifically utilizing the "Chibafreen Invitro Plant Production System", which allows for more tissue cultured plantlets to be produced in less space and less time.
Alliance Growers recently announced that it will acquire established Ontario based retailer Spyder Vapes Inc. This is the first step in the development of a true vertically integrated Seed to Sale business for Alliance Growers.
About Spyder Vapes Inc.
Founded in 2014 by entrepreneur Dan Pelchovitz, Spyder Vapes is an established chain of three high-end vape stores in Ontario. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Revenues for the initial two stores totalled $733,000 for the year ending January 31, 2018. The third store opened in December 2017.
Spyder Vapes is currently sourcing retail locations throughout Alberta and British Columbia where it seeks to establish a presence and apply for cannabis retail licences pursuant to recently announced provincial legislation. The additional retail locations will allow Spyder Vapes to leverage its retail and brand-building expertise, to offer customers quality cannabis products and, more specifically proprietary CBD products from Alliance Growers as legislation permits. Spyder Vapes' existing revenues and potential growth in the vape business will strengthen its ability to pursue opportunities in the soon to be launched recreational cannabis marketplace.
Spyder Vapes' retail and distribution focus is an ideal fit for Alliance Growers' mission to build a diversified global cannabis company focused not on where the market is today, but where it is going. Spyder Vapes neatly fits into Alliance Growers' emerging network of interests in licenced cannabis growers, cannabidiol (CBD) oil extractors, new agricultural technologies, and its own Cannabis Biotech Complex. Spyder Vapes, as the retail arm for Alliance Growers, will create a true Seed (plantlet farm) to Sale (retail stores) business for the Company and its customers.
For additional information, please visit Spyder Vapes' website at www.spydervapes.com.
If you would like to be added to Alliance Growers' news distribution list, please send your email address to firstname.lastname@example.org.
For more information contact:
CEO, President and Director
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.